Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Validation of simplified [18F]FLT PET quantification during gefitinib or erlotinib treatment in EGFR-mutant NSCLC
NL-OMON36853Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of gefitinib and erlotinib in non-small cell lung cancer (NSCLC), sponsored by Vrije University Medical Center. Primary endpoint: Association between pharmacokinetic modeling and simplified [18F]FLT PET measures during treatment. Started Nov 2012; status: active, not recruiting.
02
Drugs
gefitiniberlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON36853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36853.